A study has established the importance of immunoglobulin A, an antibody that is part of the immune system, in generating a response to pneumonia vaccines. Researchers have found that the absence of ...

IgG can sometimes trigger an undesirable response in people with autoimmune diseases, in which the immune system inadvertently attacks its own cells and tissues. Immunoglobulin A (IgA ...

Researchers at Vaxart Inc. and the Center for Vaccine Development at the University of Maryland School of Medicine evaluated ...

A new orally administered norovirus vaccine tablet has demonstrated promising safety and immunogenicity in older adults.

Biohaven Ltd. (NYSE: BHVN) ("Biohaven"), a global clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of life-changing therapies to treat a broad range ...

Gut microbiota may be the key factor explaining why certain individuals do not respond well to the pneumococcal vaccine-a bacterium that can cause various diseases, such as pneumonia.

Gut microbiota may be the key factor explaining why certain individuals do not respond well to the pneumococcal vaccine-a bacterium that can cause ...

Biohaven's BHV-1300 reduced IgG levels by up to 84% in a Phase 1 trial for autoimmune disease, with rapid and sustained effects and a favorable safety profile.

Serum was stored at −80°C. IgM, IgD, IgA, IgG, IgG1, 2, 3, and 4, and total IgE were measured. Results: The following immunoglobulins were significantly (p⩽0.05) altered after the race: IgD, ...

There were no clinically significant reductions in other immunoglobulins including IgG3, IgA, IgE, or IgM compared to baseline. Based upon the rapid and deep reductions of total IgG observed with ...